retatrutide weight loss study Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Weight Loss Study: High

& Wheeler, P

doi: 10.1155/2016/4361702

Patients utilizing Semaglutide in NYC and Tirzepatide in NYC often experience significant reductions in appetite and cravings, enhanced satiety, better blood sugar control, increased energy levels, and support for long-term weight management

HealthifyRx positions itself as a companion app for customers on weight-loss medication, and it also signed an agreement with Novo Nordisk in April 2025 to steer its patient support programme

As a single-center retrospective analysis, it may be subject to selection bias, and conclusions should be validated in large-scale multicenter prospective studies

GSM/atrophy: Offer vaginal oestrogen or non-hormonal options